Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
| dc.rights.license | open | en_US |
| dc.contributor.author | LADOUCEUR, Alexandra | |
| dc.contributor.author | BARNETCHE, Thomas | |
| dc.contributor.author | MOUTERDE, G. | |
| dc.contributor.author | TISON, A. | |
| dc.contributor.author | BITOUN, S. | |
| dc.contributor.author | PREY, Sorilla | |
| dc.contributor.author | DUTRIAUX, Caroline | |
| dc.contributor.author | GERARD, Emilie | |
| dc.contributor.author | PHAM-LEDARD, Anne | |
| dc.contributor.author | BEYLOT-BARRY, Marie | |
| dc.contributor.author | ZYSMAN, Maeva | |
| dc.contributor.author | VEILLON, Remi | |
| dc.contributor.author | DOMBLIDES, Charlotte | |
| dc.contributor.author | DASTE, A. | |
| dc.contributor.author | GROSS-GOUPIL, M. | |
| dc.contributor.author | SIONNEAU, B. | |
| dc.contributor.author | LEFORT, F. | |
| dc.contributor.author | LARROQUETTE, M. | |
| hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
| dc.contributor.author | RICHEZ, Christophe | |
| dc.contributor.author | TRUCHETET, M.-E. | |
| dc.contributor.author | SCHAEVERBEKE, T. | |
| dc.contributor.author | KOSTINE, M. | |
| dc.date.accessioned | 2024-05-03T07:05:34Z | |
| dc.date.available | 2024-05-03T07:05:34Z | |
| dc.date.issued | 2023 | |
| dc.identifier.issn | 2056-5933 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/199580 | |
| dc.description.abstractEn | Objective Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety of ICI rechallenge in this setting. We aimed to assess the rate and clinical features associated with ICI-IA flare/recurrence on ICI rechallenge. Methods We conducted a multicentre observational study including cancer patients with ICI-IA who started a second course of ICI more than 3 months after ICI discontinuation in four French university hospitals. Primary outcome was the frequency of ICI flare/recurrence after ICI rechallenge. Results Twenty-three patients were included. At the time of ICI rechallenge, 18 patients reported no symptoms of ICI-IA (78%) and 5 had grade 1 (22%), 11 patients (48%) were not receiving any ICI-IA treatment, 11 (48%) were still on prednisone, 2 (9%) were on conventional synthetic disease-modifying antirheumatic drugs and 1 (4%) on anti-IL-6. ICI-IA flare/recurrence occurred in 12 patients (52%) with a median time of 1 month after ICI rechallenge. ICI-IA phenotype, disease activity and ICI-IA treatment at the time of ICI rechallenge did not differ according to ICI-IA flare/ recurrence status. Conclusion In this first observational study of ICI-IA patients rechallenged with ICI, about half of the patients experienced ICI-IA flare/recurrence with a similar phenotype but occurring earlier than the initial ICI-IA, warranting close monitoring during the first month of retreatment. Risk of flare did not differ according to baseline immunosuppressive treatment at the time of rechallenge. © Author(s) (or their employer(s)) 2023. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
| dc.subject.en | Antirheumatic Agents; Arthritis | |
| dc.subject.en | Glucocorticoids | |
| dc.subject.en | Outcome Assessment | |
| dc.subject.en | Health Care | |
| dc.subject.en | Risk Factors | |
| dc.title.en | Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1136/rmdopen-2023-003795 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Immunologie | en_US |
| dc.identifier.pubmed | 38030233 | en_US |
| bordeaux.journal | RMD Open | en_US |
| bordeaux.volume | 9 | en_US |
| bordeaux.hal.laboratories | ImmunoConcEpT - UMR 5164 | en_US |
| bordeaux.issue | 4 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-04567146 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-05-03T07:05:38Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | CC BY-NC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=RMD%20Open&rft.date=2023&rft.volume=9&rft.issue=4&rft.eissn=2056-5933&rft.issn=2056-5933&rft.au=LADOUCEUR,%20Alexandra&BARNETCHE,%20Thomas&MOUTERDE,%20G.&TISON,%20A.&BITOUN,%20S.&rft.genre=article |
